Inventor · disambiguated record

Xuechao Xing

Also filed as: XING XUECHAO

51 granted patents·8 pending applications·186 citations·filing 2002–2025

98Inventor score

Technology areasC07D C07J A61P A61K C07C

Files withENANTA PHARM INC56 TUFTS COLLEGE2 BRIGHAM & WOMENS HOSPITAL1

Top patents by PatentIndex Score

59 records

0198US11560368B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Jan 24, 2023·6 cites·18 claims
0298US11384090B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted Jul 12, 2022·14 cites·15 claims
0398US11352363B1Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted Jun 7, 2022·13 cites·9 claims
0498US11325916B1Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted May 10, 2022·16 cites·15 claims
0598US10683279B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 16, 2020·13 cites·18 claims
0697US11420976B2Heterocyclic compounds as anti-viral agentsENANTA PHARM INC·Filed 2021·Granted Aug 23, 2022·7 cites·23 claims
0797US10988458B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 27, 2021·7 cites·23 claims
0896US11919910B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2022·Granted Mar 5, 2024·5 cites·13 claims
0995US10968249B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Apr 6, 2021·3 cites·12 claims
1095US10676500B2Process for preparation of sulfonyl carbamate bile acid derivativesENANTA PHARM INC·Filed 2018·Granted Jun 9, 2020·7 cites·8 claims
1195US10450301B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Oct 22, 2019·11 cites·20 claims
1295US10246439B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 2, 2019·12 cites·20 claims
1394US12018017B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Jun 25, 2024·1 cites·14 claims
1494US11834436B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Dec 5, 2023·2 cites·5 claims
1594US10450306B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Oct 22, 2019·7 cites·22 claims
1694US10253018B2Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Apr 9, 2019·10 cites·26 claims
1793US10696713B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 30, 2020·3 cites·15 claims
1892US10208081B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2015·Granted Feb 19, 2019·9 cites·53 claims
1991US10457703B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2016·Granted Oct 29, 2019·8 cites·16 claims
2089US11718641B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Aug 8, 2023·1 cites·5 claims
2189US11040998B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 22, 2021·2 cites·17 claims
2288US11958879B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2021·Granted Apr 16, 2024·1 cites·5 claims
2388US10080743B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·4 cites·22 claims
2487US10472386B2Bile acid derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Nov 12, 2019·6 cites·10 claims
2587US10080742B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·24 claims
2685US12281140B2Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
2785US10149835B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 11, 2018·2 cites·18 claims
2885US10080741B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Sep 25, 2018·3 cites·19 claims
2984US12459923B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2023·Granted Nov 4, 2025·0 cites·12 claims
3082US10689391B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2018·Granted Jun 23, 2020·2 cites·22 claims
3181US11008304B2Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2019·Granted May 18, 2021·1 cites·6 claims
3280US10144729B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Dec 4, 2018·2 cites·20 claims
3380US2024327452A1Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use ThereofENANTA PHARM INC·Filed 2024·Application pending·0 cites
3476US11034684B2Isoxazole analogs as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Jun 15, 2021·1 cites·22 claims
3574US10138228B2Isoxazole derivatives as FXR agonists and methods of use therofENANTA PHARM INC·Filed 2017·Granted Nov 27, 2018·1 cites·18 claims
3673US10829486B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2019·Granted Nov 10, 2020·1 cites·21 claims
3772US10597391B2Urea-containing isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2017·Granted Mar 24, 2020·1 cites·25 claims
3871US12384753B217-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofENANTA PHARM INC·Filed 2022·Granted Aug 12, 2025·0 cites·6 claims
3970US2025376452A117-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofENANTA PHARM INC·Filed 2025·Application pending·0 cites
4068US10266560B2Bile acid analogs as FXR/TGR5 agonists and methods of use thereofENANTA PHARM INC·Filed 2015·Granted Apr 23, 2019·1 cites·16 claims
4168US2024327334A1Covalent Inhibitors As Antiviral AgentsENANTA PHARM INC·Filed 2023·Application pending·0 cites
4266US10961272B2Process for preparation of sulfonyl carbamate bile acid derivativesENANTA PHARM INC·Filed 2020·Granted Mar 30, 2021·0 cites·12 claims
4366US2024207224A1Macrocyclic chalcone-amide derived antiviral agentsENANTA PHARM INC·Filed 2023·Application pending·0 cites
4466US2025059174A1Pharmaceutical Compounds and Compositions as C-Kit Kinase InhibitorsENANTA PHARM INC·Filed 2024·Application pending·0 cites
4563US12145942B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2023·Granted Nov 19, 2024·0 cites·13 claims
4660US11945824B2Heterocyclic compounds as anti-viral agentsENANTA PHARM INC·Filed 2021·Granted Apr 2, 2024·0 cites·21 claims
4759US11976084B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2021·Granted May 7, 2024·0 cites·16 claims
4858US12479854B2Spiropyrrolidine derived antiviral agentsENANTA PHARM INC·Filed 2022·Granted Nov 25, 2025·0 cites·22 claims
4953US11555032B2Isoxazole derivatives as FXR agonists and methods of use thereofENANTA PHARM INC·Filed 2020·Granted Jan 17, 2023·0 cites·17 claims
5053US7371867B2Non-racemic trifluoroleucine, and methods of making and usingTUFTS COLLEGE·Filed 2006·Granted May 13, 2008·0 cites·14 claims

Showing the top 50 of 59 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Xuechao Xing files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →